BioAtla Investor Conference Presentation Deck

Continued promising safety and tolerability profile observed in Phase 2 at the RP2D [en No treatment- related deaths bicatla Few treatment-related SAES, consistent with MMAE-based toxicity, including: Reversible myelosuppression, Transient liver enzyme elevation, Metabolic disturbances Company material-confidential 808 Few related AEs leading to treatment discontinuation + No clinically meaningful on-target toxicity observed over background BA3011 - Mecbotamab vedotin Differentiated profile due to avoiding on- target off-tumor toxicity BioAtla Overview | Company Confidential 9

View entire presentation